Prevention and Treatment of Tumor Lysis Syndrome

Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.

Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.

Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.

Expert perspectives on prophylactic measures to prevent tumor lysis syndrome in patients receiving therapy for cancer.

James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.

Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.

A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.

Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.

Anthony Perissinotti, PharmD, BCOP, highlights associated risk for tumor lysis syndrome and identifies signs and symptoms.

Expert perspective on the role of a pharmacist in managing patients with identified tumor lysis syndrome.

An overview of the prophylactic strategies that may be utilized to reduce the likelihood of tumor lysis syndrome.

Guideline-directed treatment strategies available to patients with identified tumor lysis syndrome.

Closing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.